Next Article in Journal
Influence of Culture Period on Osteoblast Differentiation of Tissue-Engineered Bone Constructed by Apatite-Fiber Scaffolds Using Radial-Flow Bioreactor
Next Article in Special Issue
Recent Advances in Anticoagulant Treatment of Immune Thrombosis: A Focus on Direct Oral Anticoagulants in Heparin-Induced Thrombocytopenia and Anti-Phospholipid Syndrome
Previous Article in Journal
Roles of a Cysteine Desulfhydrase LCD1 in Regulating Leaf Senescence in Tomato
Review

Current and Novel Antiplatelet Therapies for the Treatment of Cardiovascular Diseases

1
Research Center, Montreal Heart Institute, Montreal, QC H1T 1C8, Canada
2
Faculty of Pharmacy, Université de Montréal, Montreal, QC H3T 1J4, Canada
3
INSERM, Innovations Thérapeutiques en Hémostase, Université de Paris, F-75006 Paris, France
4
Service d’Hématologie Biologique, AP-HP, Hôpital Européen Georges Pompidou, F-75015 Paris, France
*
Authors to whom correspondence should be addressed.
Academic Editor: Lih Kuo
Int. J. Mol. Sci. 2021, 22(23), 13079; https://doi.org/10.3390/ijms222313079
Received: 5 November 2021 / Revised: 22 November 2021 / Accepted: 29 November 2021 / Published: 3 December 2021
(This article belongs to the Special Issue Recent Advances in Antithrombotic Agents)
Over the last decades, antiplatelet agents, mainly aspirin and P2Y12 receptor antagonists, have significantly reduced morbidity and mortality associated with arterial thrombosis. Their pharmacological characteristics, including pharmacokinetic/pharmacodynamics profiles, have been extensively studied, and a significant number of clinical trials assessing their efficacy and safety in various clinical settings have established antithrombotic efficacy. Notwithstanding, antiplatelet agents carry an inherent risk of bleeding. Given that bleeding is associated with adverse cardiovascular outcomes and mortality, there is an unmet clinical need to develop novel antiplatelet therapies that inhibit thrombosis while maintaining hemostasis. In this review, we present the currently available antiplatelet agents, with a particular focus on their targets, pharmacological characteristics, and patterns of use. We will further discuss the novel antiplatelet therapies in the pipeline, with the goal of improved clinical outcomes among patients with atherothrombotic diseases. View Full-Text
Keywords: acute coronary syndrome; aspirin; atherothrombosis; bleeding; cardiovascular disease; dual antiplatelet therapy; P2Y12 receptor antagonists; platelets acute coronary syndrome; aspirin; atherothrombosis; bleeding; cardiovascular disease; dual antiplatelet therapy; P2Y12 receptor antagonists; platelets
Show Figures

Figure 1

MDPI and ACS Style

Jourdi, G.; Lordkipanidzé, M.; Philippe, A.; Bachelot-Loza, C.; Gaussem, P. Current and Novel Antiplatelet Therapies for the Treatment of Cardiovascular Diseases. Int. J. Mol. Sci. 2021, 22, 13079. https://doi.org/10.3390/ijms222313079

AMA Style

Jourdi G, Lordkipanidzé M, Philippe A, Bachelot-Loza C, Gaussem P. Current and Novel Antiplatelet Therapies for the Treatment of Cardiovascular Diseases. International Journal of Molecular Sciences. 2021; 22(23):13079. https://doi.org/10.3390/ijms222313079

Chicago/Turabian Style

Jourdi, Georges, Marie Lordkipanidzé, Aurélien Philippe, Christilla Bachelot-Loza, and Pascale Gaussem. 2021. "Current and Novel Antiplatelet Therapies for the Treatment of Cardiovascular Diseases" International Journal of Molecular Sciences 22, no. 23: 13079. https://doi.org/10.3390/ijms222313079

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop